These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33919281)

  • 21. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
    Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.
    Fencer MG; Krupa KA; Bleich GC; Grumet S; Eladoumikdachi FG; Kumar S; Kowzun MJ; Potdevin LB
    Clin Breast Cancer; 2023 Jun; 23(4):e194-e199. PubMed ID: 36966080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
    Pfeifer W; Sokolenko AP; Potapova ON; Bessonov AA; Ivantsov AO; Laptiev SA; Zaitseva OA; Yatsuk OS; Matsko DE; Semiglazova TY; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2014 Dec; 148(3):675-83. PubMed ID: 25414026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
    Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
    ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
    Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
    Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    Iyevleva AG; Aleksakhina SN; Sokolenko AP; Baskina SV; Venina AR; Anisimova EI; Bizin IV; Ivantsov AO; Belysheva YV; Chernyakova AP; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2022 Apr; 192(2):283-291. PubMed ID: 35020107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
    Bubien V; Bonnet F; Dupiot-Chiron J; Barouk-Simonet E; Jones N; de Reynies A; MacGrogan G; Sevenet N; Letouzé E; Longy M
    Genes Chromosomes Cancer; 2017 Nov; 56(11):788-799. PubMed ID: 28691344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients.
    Nizic-Kos T; Krajc M; Blatnik A; Stegel V; Skerl P; Novakovic S; Gazic B; Besic N
    Ann Surg Oncol; 2021 May; 28(5):2561-2570. PubMed ID: 33030641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
    Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
    Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
    Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
    Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers.
    Borde J; Ernst C; Wappenschmidt B; Niederacher D; Weber-Lassalle K; Schmidt G; Hauke J; Quante AS; Weber-Lassalle N; Horváth J; Pohl-Rescigno E; Arnold N; Rump A; Gehrig A; Hentschel J; Faust U; Dutrannoy V; Meindl A; Kuzyakova M; Wang-Gohrke S; Weber BHF; Sutter C; Volk AE; Giannakopoulou O; Lee A; Engel C; Schmidt MK; Antoniou AC; Schmutzler RK; Kuchenbaecker K; Hahnen E
    J Natl Cancer Inst; 2021 Jul; 113(7):893-899. PubMed ID: 33372680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.